US 11,654,152 B2
Compositions for oral administration of zoledronic acid or related compounds for treating disease
Herriot Tabuteau, New York, NY (US)
Assigned to ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed by ANTECIP BIOVENTURES II LLC, New York, NY (US)
Filed on Jun. 26, 2019, as Appl. No. 16/452,910.
Application 16/452,910 is a continuation in part of application No. 15/952,017, filed on Apr. 12, 2018, granted, now 10,335,424.
Application 15/952,017 is a continuation of application No. 15/787,612, filed on Oct. 18, 2017, granted, now 9,956,238, issued on May 1, 2018.
Application 15/787,612 is a continuation in part of application No. 15/378,939, filed on Dec. 14, 2016, granted, now 9,827,256, issued on Nov. 28, 2017.
Application 15/787,612 is a continuation in part of application No. 16/452,910.
Application 16/452,910 is a continuation in part of application No. 15/365,748, filed on Nov. 30, 2016, abandoned.
Application 15/365,748 is a continuation in part of application No. 15/348,808, filed on Nov. 10, 2016, granted, now 9,700,570, issued on Jul. 11, 2017.
Application 15/348,808 is a continuation in part of application No. 15/211,827, filed on Jul. 15, 2016, granted, now 9,539,268, issued on Jan. 10, 2017.
Application 15/211,827 is a continuation in part of application No. 15/136,092, filed on Apr. 22, 2016, granted, now 9,616,078, issued on Apr. 11, 2017.
Application 15/136,092 is a continuation in part of application No. 15/043,281, filed on Feb. 12, 2016, granted, now 9,517,242, issued on Dec. 13, 2016.
Application 15/043,281 is a continuation of application No. 14/968,514, filed on Dec. 14, 2015, granted, now 9,408,862, issued on Aug. 9, 2016.
Application 14/968,514 is a continuation in part of application No. PCT/US2015/032739, filed on May 27, 2015.
Application PCT/US2015/032739 is a continuation of application No. 14/540,333, filed on Nov. 13, 2014, granted, now 9,216,168, issued on Dec. 22, 2015.
Application 14/540,333 is a continuation of application No. 14/481,097, filed on Sep. 9, 2014, granted, now 8,962,599, issued on Feb. 24, 2015.
Application 14/481,097 is a continuation of application No. PCT/US2014/050427, filed on Aug. 8, 2014.
Application PCT/US2014/050427 is a continuation of application No. 14/288,720, filed on May 28, 2014, granted, now 8,865,757, issued on Oct. 21, 2014.
Application 14/288,720 is a continuation of application No. 14/288,241, filed on May 27, 2014, granted, now 8,901,161, issued on Dec. 2, 2014.
Application 14/288,241 is a continuation of application No. 14/279,196, filed on May 15, 2014, granted, now 9,301,964, issued on Apr. 5, 2016.
Application 14/279,196 is a continuation of application No. 14/279,241, filed on May 15, 2014, abandoned.
Application 14/279,241 is a continuation of application No. 14/063,979, filed on Oct. 25, 2013, granted, now 8,802,658, issued on Aug. 12, 2014.
Application 14/063,979 is a continuation in part of application No. 13/894,274, filed on May 14, 2013, abandoned.
Claims priority of provisional application 62/150,871, filed on Apr. 22, 2015.
Claims priority of provisional application 61/803,721, filed on Mar. 20, 2013.
Claims priority of provisional application 61/767,676, filed on Feb. 21, 2013.
Claims priority of provisional application 61/767,647, filed on Feb. 21, 2013.
Claims priority of provisional application 61/764,563, filed on Feb. 14, 2013.
Claims priority of provisional application 61/762,225, filed on Feb. 7, 2013.
Claims priority of provisional application 61/655,527, filed on Jun. 5, 2012.
Claims priority of provisional application 61/655,541, filed on Jun. 5, 2012.
Claims priority of provisional application 61/654,383, filed on Jun. 1, 2012.
Claims priority of provisional application 61/654,292, filed on Jun. 1, 2012.
Claims priority of provisional application 61/647,478, filed on May 15, 2012.
Claims priority of provisional application 61/646,538, filed on May 14, 2012.
Prior Publication US 2019/0314391 A1, Oct. 17, 2019
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/675 (2006.01); A61K 9/28 (2006.01); A61K 9/20 (2006.01); A61K 9/00 (2006.01); A61K 47/12 (2006.01); A61K 45/06 (2006.01); C07F 9/6506 (2006.01); A61K 31/663 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 9/0053 (2013.01); A61K 9/20 (2013.01); A61K 9/2004 (2013.01); A61K 9/28 (2013.01); A61K 31/663 (2013.01); A61K 45/06 (2013.01); A61K 47/12 (2013.01); C07F 9/6506 (2013.01); A61K 9/0095 (2013.01)] 30 Claims
 
1. A method of treating arthritis comprising orally administering a zoledronic acid to a human being suffering from arthritis, wherein the zoledronic acid is in a salt form, wherein the human being is fasted for at least 2 hours prior to receiving the salt form of zoledronic acid and the human being is fasted for at least 1 hour after receiving the salt form of zoledronic acid, wherein the salt form of zoledronic acid has a bioavailability that is 1.1% to about 4%, and wherein the human being experiences pain relief as a result of receiving the zoledronic acid.